Microbot Medical Inc. announced on January 21, 2025, the appointment of Ms. Michal Ahuvia to the newly created role of Director of Operations. This addition strengthens the company's management team in support of the anticipated commercial launch of its LIBERTY Endovascular Robotic System.
In her new role, Ms. Ahuvia will be responsible for ramping up production and improving product cost reduction activities. Her focus on operational efficiencies is crucial as Microbot Medical transitions from a clinical-stage to a commercial-stage company.
This strategic hire underscores Microbot Medical's commitment to building the necessary infrastructure for a successful market entry. Enhancing manufacturing capabilities and managing costs are key factors for the commercial viability of the LIBERTY system.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.